Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Zocor Rhabdomyolysis Risk Is Dose-Related, Revised Warning Says

Executive Summary

The risk of myopathy and rhabdomyolysis associated with Merck's Zocor (simvastatin) increases in proportion to the dose, revised labeling says

You may also be interested in...



Schering-Plough Zetia Could Be More Important Growth Product Than Claritin

Schering-Plough's cholesterol agent Zetia could be an even larger growth driver than Claritin, CEO Richard Kogan told analysts at the company's annual meeting on July 16

Schering-Plough Zetia Could Be More Important Growth Product Than Claritin

Schering-Plough's cholesterol agent Zetia could be an even larger growth driver than Claritin, CEO Richard Kogan told analysts at the company's annual meeting on July 16

AstraZeneca Crestor 80 Mg Dose Would Have Low Demand, CEO Suggests

AstraZeneca expects that an 80 mg strength of Crestor, if approved, would constitute a small proportion of the product's sales

Related Content

UsernamePublicRestriction

Register

PS039978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel